title: Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET.
abstract: OBJECTIVE
  This study employed 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]FLT) microPET scanning to assess the treatment response of histone deacetylase inhibitors (HDACi), e.g., N1-hydroxy-N8-phenyloctanediamide (SAHA) and its iodinated derivative ISAHA, in a hepatoma mouse model.
  
  
  METHODS
  The in vitro cytotoxicity of HDACi in various hepatoma cell lines was determined by MTT assay and flow cytometry. ISAHA and SAHA were used to treat HepG2 hepatoma xenograft-bearing mice. The treatment responses were characterized in terms of tumor burden, microPET imaging, and immunohistochemical staining of tumor sections.
  
  
  RESULTS
  ISAHA effectively inhibited HepG2 hepatoma cell survival and tumor growth. A significantly reduced tumor uptake during HDACi treatment was noticed in [(18)F]FLT microPET imaging, which was consistent with the findings in immunohistochemical staining.
  
  
  CONCLUSIONS
  ISAHA can suppress tumor cell proliferation both in vitro and in vivo. [(18)F]FLT PET is a promising modality for evaluating the in vivo therapeutic efficacy of HDACi at the early stage of treatment.
authors.affiliation: Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.
authors.forename: Pei-Chia
authors.initials: PC
authors.lastname: Chan
authors.forename: Chun-Yi
authors.initials: CY
authors.lastname: Wu
authors.forename: Lin-Shan
authors.initials: LS
authors.lastname: Chou
authors.forename: Chung-Hsien
authors.initials: CH
authors.lastname: Ho
authors.forename: Chi-Wei
authors.initials: CW
authors.lastname: Chang
authors.forename: Shih-Hwa
authors.initials: SH
authors.lastname: Chiou
authors.forename: Wuu-Jyh
authors.initials: WJ
authors.lastname: Lin
authors.forename: Fu-Du
authors.initials: FD
authors.lastname: Chen
authors.forename: C Allen
authors.initials: CA
authors.lastname: Chang
authors.forename: Jeng-Jong
authors.initials: JJ
authors.lastname: Hwang
authors.forename: Ren-Shyan
authors.initials: RS
authors.lastname: Liu
authors.forename: Hsin-Ell
authors.initials: HE
authors.lastname: Wang
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002453:Cell Cycle; D049109:Cell Proliferation; D002470:Cell Survival; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry*; D056945:Hep G2 Cells; D056572:Histone Deacetylase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D049268:Positron-Emission Tomography; D000077337:Vorinostat
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D019788:Fluorodeoxyglucose F18; D000077337:Vorinostat